1. MMV-supported projects
Research
Translational
Product development
Access
Lead optimization
Candidate profiling
Human volunteers
Patient exploratory
Patient confirmatory
Regulatory review
Preclinical
Approved/ERP
Miniportfolio
GSK
Miniportfolio
Novartis
MMV
Novartis
MMV533
Sanofi
P218
Janssen
Ferroquine / Artefenomel
Sanofi
Dihydroartemisinin- piperaquine dispersible
Alfasigma
Artemether-
lumefantrine
Dispersible
Novartis
Sulfadoxine-
pyrimethamine+
amodiaquine dispersible
Fosun Pharma 4 1 7
Phenotypic Lead
Mitsubishi Tanabe
SJ733 backup
Kentucky
MMV370
MMV371
Janssen
M5717
Merck KGaA
Ganaplacide /
Lumefantrine
Novartis
Tafenoquine paediatric GSK
Artesunate
for Injection
Fosun Pharma
Sulfadoxine-
pyrimethamine+
amodiaquine dispersible S Kant 2
Open Source Series
University of Sydney
Molecular Target
UCB
MMV183
(TropIQ)
MMV253
Zydus Cadila
Cipargamin
Novartis
Sulfadoxine-
pyrimethamine Universal Corporation
Artesunate
for Injection
Ipca 8 3
Artesunate rectal capsules
Cipla
Purines
Celgene
DHODH
Broad
Atoguanil
Ipca
DSM265
(Takeda)
Artemether lumefantrine <5kg Novartis
Dihydroartemisinin- piperaquine
Alfasigma 9
MMV646
(Jacobus) 4
Artesunate rectal capsules
Strides Pharma
GWT1
Eisai
DHODH
UTSW/ UW/ Monash
MMV048
(UCT)
Pyronaridine-
artesunate
Shin Poong 10
INE693
Novartis 5
Tafenoquine
GSK
Molecular Target
DDU Dundee
Phenotypic Lead
Merck KGaA-UCT
Pyronaridine- artesunate granules
Shin Poong 11 5
Azabenzimidazole
UNICAMP
Intra-muscular
Calibr
Artesunate-
amodiaquine
Sanofi 6
MMV support to projects may include financial, in-kind, and advisory activities.
Footnotes: Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ. │ Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing. │ WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers. │ paediatric formulation.│ via a bioequivalence study. Past partners are in brackets (-).
Artesunate-
mefloquine
Cipla
Brand names 1: Coartem® Dispersible; 2: Artesun®; 3: Larinate® 60mg; 4: Eurartesim®; 5: Pyramax® tablets or granules; 6: ASAQ Winthrop®; 7: SPAQ-COTM; 8: Supyra® 9: 100mg Artesunate Rectocaps; 10: ArtecapTM; 11: Kozenis/Krintafel (Trademarks owned or licensed by GSK)

2. Footnotes: MMV-supported projects
Target Product Profiles and Target Candidate Profiles
MMV has defined Target Product Profiles and Target Candidate Profiles for medicines to support the eradication campaign.
Burrows JN et al., New developments in anti‑malarial target candidate and product profiles et al. Malar J (2017) 16:26 updates the previous profiles in Burrows J et al.; Malaria Journal :187
Target Product Profiles
indicated by bars at the bottom of each compound box
Target Candidate Profiles
activities for each individual molecule, indicated by symbols added to compounds in the translational or product development portfolio
Burrows Burrows
et al., 2013 et al., 2017
Asexual blood stages (TCP-1,2) TCP-1
Relapse prevention (TCP-3a) TCP-3
Transmission reduction (TCP-3b) TCP-5,6
Prophylaxis (TCP- 4) TCP-4
3-day cure, artemisinin-based combination therapies
Uncomplicated malaria treatments for single-exposure radical cure (SERC) and/or resistance management (TPP-1)
Severe malaria treatment / pre-referral intervention
Intermittent /seasonal malaria chemoprevention
Products targeting prevention of relapse for P. vivax
Single-exposure chemoprotection (SEC) TPP-2